Reuters logo
BRIEF-Amgen says new retrospective analyses confirm Vectibix treatment provided survival benefit over chemotherapy with or without Bevacizumab
October 10, 2016 / 1:26 PM / a year ago

BRIEF-Amgen says new retrospective analyses confirm Vectibix treatment provided survival benefit over chemotherapy with or without Bevacizumab

Oct 10 (Reuters) - Amgen Inc :

* New retrospective analyses confirm Vectibix (panitumumab) treatment provided survival benefit over chemotherapy with or without bevacizumab in metastatic colorectal cancer patients with tumors of left-sided origin Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below